TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04038021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phosphatidylethanol-based Contingency Management
Description: In CM, tangible reinforcers are provided after individuals demonstrate biochemically verified abstinence of various substances. CM is associated with increased abstinence from illicit drugs, nicotine, and alcohol and is the most powerful psychosocial treatment for initiating abstinence of these substances. When participants submit a negative result for alcohol (via blood phosphatidylethanol biomarkers), the subject will receive rewards (gift cards). In contrast, they will not receive rewards when their samples test positive for alcohol.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Contingent Control
Description: In the non-contingent control intervention, participants will receive rewards (gift cards) regardless of the alcohol biomarker results in their samples. Once the samples have been received, the subjects will receive reinforcers that is consistent with the average from the CM group's earnings.
Study: NCT03839797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cadet Healthy Personal Skills
Description: 7.5 hour skills training group intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Health Education
Description: Standard Health Education
Study: NCT03330249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Split Cisplatin
Description: 25 mg/m2/day IV infusion at D1 to D4, at D22 to D25, at D43 to D46 during the radiotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 100 mg/m2/day IV infusion at D1, D22 and D43 during the radiotherapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 70 Gy in 35 fractions of 2 Gy in non-operated patients and 66 Gy in 33 fractions in post-operative.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 70 Gy in 35 fractions of 2 Gy in non-operated patients and 66 Gy in 33 fractions in post-operative.
Study: NCT04919200

Intervention type: DIAGNOSTIC_TEST
Intervention: the single-breath helium dilution method and Whole-body plethysmography
Description: The patients with obstructive lung disease simultaneously subjected to the single-breath helium dilution method and Whole-body plethysmography tests.

Intervention type: DIAGNOSTIC_TEST
Intervention: the single-breath helium dilution method and Whole-body plethysmography
Description: The patients with obstructive lung disease simultaneously subjected to the single-breath helium dilution method and Whole-body plethysmography tests.
Study: NCT03705143

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as Usual participants will receive the treatment typically provided to patients at the MMT clinic in Wuhan, China.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chinese translated LETS ACT
Description: The Chinese translated Behavioral Activation (C-BA) will be provided in Mandarin. C-BA treatment includes psychoeducation regarding the link between mood and behavior, identification of values/goals/activities across life areas, planning and tracking of daily value driven activities.
Study: NCT03841201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: iv infusion
Study: NCT02893956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: echocardiography with postural support

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: echocardiography with postural support

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: echocardiography with standard condition (usual)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: echocardiography with standard condition (usual)
Study: NCT04057976

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Probabilistic diffusion tensor tractography
Description: Patients enrolled in this study will undergo probabilistic diffusion tensor tractography (additional MRI sequence) preoperatively in order to determine whether this it is possible to determine the course of the facial nerve.
Study: NCT02809001

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat grafting
Description: In the experimental group, liposuction will be performed and autologous fat graft will be harvest after washing with saline. Patients will receive autologous fat graft transplantation subdermally to expanded skin.
Study: NCT01354314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: One 100 MG capsule taken twice daily, 12 hour dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Two 10 MG capsules paroxetine once daily in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine and Fluconazole
Description: One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule in the morning, three capsules in the evening
Study: NCT02806102

Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention

Intervention type: DRUG
Intervention: Dual-antiplatelet therapy
Description: Dual AntiPlatelet Therapy

Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention

Intervention type: DRUG
Intervention: Dual-antiplatelet therapy
Description: Dual AntiPlatelet Therapy
Study: NCT02271672

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XP1000 RF
Description: Treatment of adipose tissue within the fat layer with XP1000 RF.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham XP1000 RF
Description: Treatment of adipose tissue within the fat layer with XP1000 RF.
Study: NCT00003278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01010646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN alfa-2b XL 27 MUI + Ribavirin
Description: IFN alfa-2b XL 27 MUI administered once a week for 12 weeks by subcutaneous injections, in combination with weight dosed ribavirin daily administered orally in two divided doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFN alfa-2b XL 36 MUI + Ribavirin
Description: IFN alfa-2b XL 36 MUI administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IFN peg alfa-2b 1.5 µg/kg + Ribavirin
Description: IFN peg alfa-2b 1.5 µg/kg administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses
Study: NCT01356277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action-focused problem-solving
Description: * Adherence Support Team (patient, parent, Coach)~* standardized education on immunosuppressive medications~* identification of adherence barriers~* 'Action-Focused Problem-Solving' to address barriers selected as most important by the patient

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic pillbox monitoring, dose reminders, and feedback
Description: * Electronic adherence monitoring with feedback of past 3 months of electronic monitoring data at 3-month intervals~* text message, email, or visual cue dose reminders
Study: NCT01740648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Description: Trametinib will be given for 5-day lead-in period by mouth daily Monday-Friday starting at day -14 through -10 and concurrently for the duration of radiation therapy (approximately days 1-38).The dose of Trametinib will be escalated: 0.5 mg, 1.0 mg, 2mg. If the 2 mg dose level causes DLT (dose-limiting toxicity)in 2 out of 6 patients and the 1mg dose level was acceptable, then a 1.5 mg dose cohort will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Will be administered as a continuous infusion over 120 hours at a dose of 225 mg/m2/day on Monday to Friday of every week starting day 1-38.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiation therapy will be delivered to the pelvis during (approximately) days 1-33 (five days a week, Mondays through Fridays for 25 fractions) using a 3-field or 4-field 3-D conformal plan to the primary tumor, surrounding soft tissues, and at risk lymph node stations (peri-rectal, presacral, internal iliac, with or without external iliac) to a total dose of 45 Gy in 1.8 Gy daily fractions. A boost radiation field will be delivered during (approximately) days 36-38. The boost will encompass the primary rectal tumor and involved lymph nodes with a 2-2.5 cm margin, which should include the presacral space. The boost dose will be 5.4 Gy in 1.8 Gy fractions for a total dose of 50.4 Gy.
Study: NCT03895749

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NEO40 Daily
Description: Per Capsule: N5-carbamoylornithine 100 mg, crataegus laevigata 100 mg, L-ascorbic acid 50 mg, vitamin B-12 0.05 mg, vitamin C 50 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NEO40 Daily
Description: Per Capsule: N5-carbamoylornithine 100 mg, crataegus laevigata 100 mg, L-ascorbic acid 50 mg, vitamin B-12 0.05 mg, vitamin C 50 mg.
Study: NCT01167504

Intervention type: OTHER
Intervention: Saliva sample collection
Description: Collection of either whole mouth saliva or parotid saliva. Whole mouth saliva is collected through stimulation by inert gum. Parotid saliva is collected by using a Lashley cup placed over the parotid duct and stimulated by a fruit sweet.
Study: NCT00783107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine Inhalation Solution, Once Daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02682043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toy car
Description: The intervention is the provision of an electric toy car. This toy car will be modified to meet the postural and hand control preference of each child participant.~The child will have the toy car for an 8 week trial period. Parents and child will be instructed in the safe use of the toy car, given written guidelines, and encouraged to use frequently.~Parents will keep a log of what days they use the toy car, where and for how long.
Study: NCT00722306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: Extemporaneous solution of C14 Labelled PD 0200390 60 mg single dose
Study: NCT03899922

Intervention type: DRUG
Intervention: Drugs inducing uveitis
Description: Drugs susceptible to induce uveitis
Study: NCT03233581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit + Facebook + Coaching Group
Description: Participants will use the FitBit device to track their physical activity (PA). Participants will receive and post messages and receive badges on the Facebook group. Weekly a research staff member will call them to provide brief health coaching. Participants will select an adult family member or friend to also receive a Fitbit during the intervention period to provide support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit only
Description: Participants will receive a Fitbit device only, and will not receive health coaching, join the Facebook group, or select an adult family member or friend to receive a Fitbit to provide them with support.
Study: NCT00135343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanvir/ritonavir + efavirenz
Description: Capsules (ATV and RTV) Tablets (EFV), Oral, ATV 300 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanvir/ritonavir + efavirenz
Description: Capsules (ATV and RTV) Tablets (EFV), Oral ATV 400 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks.
Study: NCT01290770

Intervention type: OTHER
Intervention: blood sample
Description: blood sample at inclusion and 1 month after inclusion
Study: NCT02781259

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary lymph node dissection
Description: Lymph node dissection is performed in axillary lymph node level I and II. In case of palpable nodes in level II, additional lymph node dissection in level III is done.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: 10cc of 20μg/mL indocyanine green is injected at the nipple-areola complex before surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Imaging devices
Description: Near-infrared fluorescence is collected by imaging lenses and digital camera.
Study: NCT04573582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: 100 mg enasidenib (CC-90007)
Study: NCT02963285

Intervention type: OTHER
Intervention: Nasopharyngeal temperature probe
Description: Nasopharyngeal temperatures will initially be recorded 30 minutes after induction of anesthesia. Nasopharyngeal probes will then be withdrawn at the designated increment for each age group and will be equilibrated for 3 minutes before the temperature is recorded. Thereafter, the nasopharyngeal withdrawal sequence will be repeated.

Intervention type: OTHER
Intervention: Nasopharyngeal temperature probe
Description: Nasopharyngeal temperatures will initially be recorded 30 minutes after induction of anesthesia. Nasopharyngeal probes will then be withdrawn at the designated increment for each age group and will be equilibrated for 3 minutes before the temperature is recorded. Thereafter, the nasopharyngeal withdrawal sequence will be repeated.

Intervention type: OTHER
Intervention: Nasopharyngeal temperature probe
Description: Nasopharyngeal temperatures will initially be recorded 30 minutes after induction of anesthesia. Nasopharyngeal probes will then be withdrawn at the designated increment for each age group and will be equilibrated for 3 minutes before the temperature is recorded. Thereafter, the nasopharyngeal withdrawal sequence will be repeated.

Intervention type: OTHER
Intervention: Nasopharyngeal temperature probe
Description: Nasopharyngeal temperatures will initially be recorded 30 minutes after induction of anesthesia. Nasopharyngeal probes will then be withdrawn at the designated increment for each age group and will be equilibrated for 3 minutes before the temperature is recorded. Thereafter, the nasopharyngeal withdrawal sequence will be repeated.

Intervention type: OTHER
Intervention: Nasopharyngeal temperature probe
Description: Nasopharyngeal temperatures will initially be recorded 30 minutes after induction of anesthesia. Nasopharyngeal probes will then be withdrawn at the designated increment for each age group and will be equilibrated for 3 minutes before the temperature is recorded. Thereafter, the nasopharyngeal withdrawal sequence will be repeated.
Study: NCT02721966

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Anti IL-17a monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Anti IL-17a monoclonal antibody

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Secukinumab
Description: Anti IL-17a monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Secukinumab and Placebo
Description: Placebo matching AIN457
Study: NCT01021891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere®/Insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere®/Insulin
Study: NCT03070964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plitidepsin
Study: NCT03192553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Double Gloving Procedure
Description: Participants will doff PPE using a double gloving procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensified Hand Hygiene Procedure
Description: Participants will doff PPE using an intensified hand hygiene procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One Step Procedure
Description: Participants will doff PPE using a one-step procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CDC Procedure
Description: Participants will doff PPE using a CDC recommended procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
Study: NCT02175030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copper IUD
Description: Randomization to copper/Paragard IUD for emergency contraception

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel IUD
Description: Randomization to Levonorgestrel/Mirena IUD for emergency contraception
Study: NCT03179319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyChoices
Description: Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
Study: NCT03651401

Intervention type: DEVICE
Intervention: Scapular muscle endurance test
Description: The SME test, developed by Edmondston et al. 17, is based on an exercise used to improve the performance of the serratus anterior and trapezius muscles. The test was carried out while the subjects were facing the wall in standing position and with their shoulders and elbows flexed to 90 degrees. While both scapulae were in neutral position, an appropriate size of stick (18-36 cm) was selected and placed between the elbows, and they were asked to hold the dynamometer (Feta 137 F0202 1 kg/10 N) between their hands.

Intervention type: DEVICE
Intervention: Scapular muscle endurance test
Description: The SME test, developed by Edmondston et al. 17, is based on an exercise used to improve the performance of the serratus anterior and trapezius muscles. The test was carried out while the subjects were facing the wall in standing position and with their shoulders and elbows flexed to 90 degrees. While both scapulae were in neutral position, an appropriate size of stick (18-36 cm) was selected and placed between the elbows, and they were asked to hold the dynamometer (Feta 137 F0202 1 kg/10 N) between their hands.

Intervention type: OTHER
Intervention: Pain intensity
Description: Pain intensity assessment was performed by questioning rest, activity, night, and measuremant pain using a visual analogue scale (VAS) on a 10 cm line with marks at both ends to define the limits of the pain experience as no pain (0) and maximum pain experienced (10), with higher scores indicating greater pain 20.

Intervention type: DEVICE
Intervention: Upper Limb Functional Performance
Description: The Functional Impairment Test-Hand and Neck/Shoulder/Arm (FIT-HaNSA) protocol, which was developed by MacDermid et al. 21, was used to evaluate the functional performance of the upper extremity when performing 3 tasks.

Intervention type: DEVICE
Intervention: Upper Limb Functional Performance
Description: The Functional Impairment Test-Hand and Neck/Shoulder/Arm (FIT-HaNSA) protocol, which was developed by MacDermid et al. 21, was used to evaluate the functional performance of the upper extremity when performing 3 tasks.
Study: NCT03901872

Intervention type: DEVICE
Intervention: Contemporary endovascular venous intervention by Zelante pharmacomechanical thrombolysis
Description: All patients will undergo ultrasound guided micro puncture venous access of the enrolled ipsilateral lower extremity popliteal vein followed by a diagnostic venogram to define thrombus burden and anatomic extent of DVT. Prior to and every 30 minutes during the endovascular procedure, an activated clotting time (ACT) will be obtained. Intravenous unfractionated heparin will be administered to keep the ACT between 250 - 300. A Zelante catheter will be utilised to perform pharmacomechanical thrombolysis of the enrolled lower extremity. If there is involvement of the popliteal and/or femoral vein, pharmacomechanical thrombolysis should also be performed of these veins. Venous stenting may be implemented to address areas of residual venous stenosis or outflow obstruction following pharmacomechanical thrombolysis. Stent placement in the common iliac, external iliac, and common femoral vein are routinely done to address inflow or outflow issues after pharmacomechanical thrombolysis.
Study: NCT03309735

Intervention type: DRUG
Intervention: Micronized progesterone
Description: Utrogestan, 200 mg orally thrice a day until acute symptoms of the threat of termination of pregnancy (scarlet discharge from the genital tract, pain in the abdomen) and then Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed

Intervention type: DRUG
Intervention: Micronized progesterone
Description: Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed

Intervention type: DRUG
Intervention: Dydrogesterone
Description: Duphaston, orally 40 mg once, then 10 mg every 8 hours until the symptoms disappear
Study: NCT02037230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1775
Description: MK-1775 will be given as an oral capsule on days 1 and 2, and on days 8 and 9 of every 3-week cycle .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1 and 8 of a 3 -week treatment cycle.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 52.5Gy in 25 fractions (2.1Gy/fraction), using intensity modulated radiation therapy (IMRT). Radiation therapy will be administered after chemotherapy.
Study: NCT00885534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, Vinblastine, Temozolomide
Description: Patients will receive CVT chemotherapy which consists of the following:~Cisplatin 25 mg/m2 given intravenously on days 2-5 Vinblastine 1.5 mg/m2 given as an intravenous push on days 2-5 Temozolomide 150 mg/m2 given orally on days 1-5. In patients who cannot receive temozolomide, dacarbazine can be used instead. Dacarbazine will be given at 800 mg/m2 IV on day 1.
Study: NCT02608671

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin adhesive tape
Study: NCT02486185

Intervention type: OTHER
Group type: OTHER
Intervention: SCREENING TEST
Description: * Skeletal muscle mass, which will be estimated by calculating values for the mid-arm muscle circumference (MAMC) from brachial perimeter (BP) and triceps skinfold thickness (TSF).~* Muscle force will be measured using a hydraulic dynamometer~* Physical performance will be estimated from the subject's Gait speed using a 4 meter gait test (Gait speed 4-m)
Study: NCT01486095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AXXESS + Biomatrix Biolimus Eluting stent
Description: NAP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Culotte technique with Xience V or Xience Prime stents
Description: NAP